Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Interest Income

Income earned on cash, deposits, and investments held by the company.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $300K fell 2.9% year over year, ahead of the -64.4% change in trailing-twelve-month interest income. Sequentially, it rose 19.0% from the prior quarter. Over 3 fiscal years it compounded at -48.3% a year.

Context

  • Interest income amounted to 3.3% of revenue in FY2025, down 6.8 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -2.9% holds above the trailing-twelve-month pace of -64.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$300K+19.0% QoQ
Last fiscal yearDec 2025
$1.3M-77.8% YoY
LTMMar 2026
$1.29M-64.4% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.9%——
1 year-77.8%——
3-year CAGR-48.3%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
1.3M USD
Year-over-year change
-77.8%
4-year CAGR
-29.8%

Interest Income vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -64.4% is the lowest of 10, against a peer median of -27.7%.
  • Interest income amounts to 3.7% of revenue for SGMO, versus a peer median of 13.2%.
SGMO Competitors
Interest Income for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CCCCC4 Therapeutics, Inc.LTM Mar 2026$10.16M USD-24.2%+42.5%29.2%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$3.96M USD+2.3%+32.5%221.7%
IVVDInvivyd, Inc.LTM Mar 2026$3.62M USD+21.1%—6.5%
CDXSCodexis, Inc.LTM Mar 2026$2.54M USD-27.7%+22.1%3.3%
OABIOmniAb, Inc.LTM Mar 2026$2.32M USD-12.9%+65.5%8.0%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.48M CHF-47.8%+8.4%—
IPHAInnate Pharma S.A.FY2025€1.32M EUR-45.9%+34.1%47.3%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$1.29M USD-64.4%-48.3%3.7%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$1.02M USD-28.6%-12.8%32.2%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$389K USD-44.7%+137.4%13.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SGMO) —-27.7%+33.3%13.2%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.7M111.3M176.23M57.8M39.55M
Cost of Revenue012.11M007.6M
Gross Profit110.7M99.19M176.23M57.8M31.95M
Gross Margin100.0%89.1%100.0%100.0%80.8%
Research & Development230.82M249.9M234.06M111.52M112.67M
Selling, General & Admin63.22M62.68M61.17M44.73M34.89M
Operating Expenses294.04M300.47M450.24M161.77M139.95M
Depreciation & Amortization17.64M12.11M22.19M9.36M7.6M
EBITDA(160.35M)(179.74M)(96.8M)(89.09M)(115.9M)
EBITDA Margin-144.9%-161.5%-54.9%-154.1%-293.0%
Operating Income(183.34M)(201.28M)(274.01M)(103.97M)(108M)
Operating Margin-165.6%-180.8%-155.5%-179.9%-273.1%
Interest Income5.35M9.43M11.1M5.86M1.3M
Interest Expense00000
Other Income / Expenses5.35M9.43M11.1M5.86M(15.5M)
Income Before Tax(177.99M)(191.85M)(262.9M)(98.11M)(123.5M)
Pre-Tax Margin-160.8%-172.4%-149.2%-169.7%-312.2%
Income Tax Expense306K429K(5.07M)(167K)(568K)
Net Income(178.29M)(192.28M)(257.83M)(97.94M)(122.93M)
Net Margin-161.1%-172.8%-146.3%-169.4%-310.8%
EPS (Basic)(1.23)(1.25)(1.48)(0.49)(0.44)
EPS (Diluted)(1.23)(1.25)(1.48)(0.49)(0.44)
Weighted Avg Shares144.57M154.35M174.44M201.7M280.19M
Weighted Avg Shares (Diluted)144.57M154.35M174.44M201.7M280.19M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.